OmniAb, Inc.
$1.55
▼
-1.28%
2026-04-21 08:34:01
www.omniab.com
NGM: OABI
Explore OmniAb, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$237.44 M
Current Price
$1.55
52W High / Low
$2.29 / $1.22
Stock P/E
—
Book Value
$1.85
Dividend Yield
—
ROCE
-24.23%
ROE
-23.36%
Face Value
—
EPS
$-0.57
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
89
Beta
0.87
Debt / Equity
7.62
Current Ratio
4.02
Quick Ratio
4.02
Forward P/E
-4.9
Price / Sales
11.4
Enterprise Value
$179.14 M
EV / EBITDA
-3.82
EV / Revenue
9.6
Rating
Strong Buy
Target Price
$7.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 2. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 3. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
| 4. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 5. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 6. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 7. | IN8bio, Inc. | $1.5 | — | $14.77 M | — | -68.2% | -92.49% | $5.82 / $1.17 | $2.82 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 8.38 M | 2.24 M | 3.9 M | 4.15 M | 10.8 M |
| Operating Profit | -15.77 M | -18.14 M | -19.22 M | -18.84 M | -15.88 M |
| Net Profit | -14.18 M | -16.52 M | -15.88 M | -18.2 M | -13.07 M |
| EPS in Rs | -0.1 | -0.11 | -0.11 | -0.13 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 18.67 M | 26.39 M | 34.16 M | 59.08 M |
| Operating Profit | -68.97 M | -74.5 M | -69.42 M | -26.65 M |
| Net Profit | -64.78 M | -62.03 M | -50.62 M | -22.33 M |
| EPS in Rs | -0.45 | -0.43 | -0.35 | -0.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 300.91 M | 325.56 M | 375.23 M | 421.21 M |
| Total Liabilities | 33.89 M | 37.94 M | 60.64 M | 79.84 M |
| Equity | 267.03 M | 287.62 M | 314.58 M | 341.37 M |
| Current Assets | 65.34 M | 68.14 M | 94.9 M | 124.95 M |
| Current Liabilities | 16.25 M | 15.09 M | 23.12 M | 26.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -36.45 M | -39.66 M | 2.35 M | -3.59 M |
| Investing CF | 6.47 M | 37.88 M | -18.38 M | -73.31 M |
| Financing CF | 27.91 M | 13.02 M | -0.89 M | 110.74 M |
| Free CF | -37.02 M | -41.54 M | 0.7 M | -20.75 M |
| Capex | -0.56 M | -1.88 M | -1.64 M | -17.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -22.75% | -42.17% | — | — |
| Earnings Growth % | -22.55% | -126.65% | — | — |
| Profit Margin % | -235.05% | -148.16% | -37.8% | — |
| Operating Margin % | -282.3% | -203.19% | -45.11% | — |
| Gross Margin % | 100% | — | — | — |
| EBITDA Margin % | -192.94% | -146.12% | -14.22% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.